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TsCysti was exclusively endemic (2).
The contaminated areas in Irian Jaya
have increased from the central area
(Paniai), to the east (Jayawijaya) (3),
and then to the west (Manokwari),
where 54 TsCysti cases have been
reported (Papua Province Health
Office Services, 1997, unpub. data).
We wanted to know if taeniasis/cys-
ticercosis had been introduced into
the eastern half of New Guinea Island,
called Papua New Guinea (PNG) (9).
We had already serologically con-
firmed that 16 (3.0%) of 541 local res-
idents and Irianese refugees in Alice
River villages along the border in
PNG had asymptomatic TsCysti (Ito
et al., unpub. data). Follow-up sur-
veys will be crucial in several other
districts including Merauke District in
Irian Jaya, PNG, and other islands
such as Timor Island, where most of
the population is Christian and many
suspected cases have recently been
reported by the District Health Office
Services (10). Schoolchildren should
also be checked so that cases can be
detected and treated early. Sustainable
education of the local community in
Irian Jaya, Indonesia, and Papua New
Guinea is also necessary.
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Recombinant
Vaccine–Derived
Poliovirus in
Madagascar 
To the Editor: Between October
2001 and April 2002, five cases of
acute flaccid paralysis associated with
vaccine-derived poliovirus (VDPV)
type 2 isolates were reported in the
southern province of the Republic of
Madagascar. The first patient, an 11-
year-old child from the urban district
of Toliara, first experienced paralysis
on October 29, 2001. Three other chil-
dren, 6, 9, and 14 months of age from
Ebakika village, in a rural district of
Taolagnaro (250 miles east of Toliara),
showed signs of poliomyelitis
between March 21 and March 26,
2002. The last case-patient, a 20-
month-old child from Ambanihazo
village (6 miles north of Ebakika),
came into contact with one of the three
case-patients in Ebakika in March
2002, and symptoms developed on
April 12, 2002 (1). None of the
patients had been fully vaccinated
against poliomyelitis.
Nine type 2 poliovirus (PV) strains
were isolated. A restriction fragment
length polymorphism (RFLP) assay,
with  three different genomic regions
amplified by reverse transcription–
polymerase chain reaction (RT-PCR)
and four different restriction enzymes
(HinfI, DpnII, RsaI, and DdeI) were
used to characterize the PV isolates at
the molecular level (2). The RFLP
profiles of all of the isolates in the two
capsid protein regions were identical
to that of the type 2 strain of the oral
polio vaccine (OPV) in the VP1-2A
region (nucleotides 2,872 to 3,647)
but slightly different in the VP3-VP1
region (nucleotides 1,915 to 2,883).
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to distinguish two groups (isolates
from Toliara and isolates from
Taolagnaro) and two subgroups (iso-
lates from March and isolates from
April). The RFLP profiles of isolates
in the noncapsid region, at the 3′-ter-
minal end of the genome (polymerase
3D and 3′ noncoding regions:
nucleotides 6,535 to 7,439) also con-
firmed the presence of two separate
groups. These last profiles were com-
pletely different from those of the
three reference vaccine strains, sug-
gesting recombination with other
enteroviruses.
Partial genomic sequencing con-
firmed these observations. The entire
VP1 region (903 nucleotides) of the
type 2 PV strains from Toliara and
Taolagnaro differed from the type 2
OPV strain by 1% and 2.5%
nucleotides, respectively. This differ-
ence may indicate that the two strains
had been multiplying or circulating
for approximately 1 and 2.5 years,
respectively. Taolagnaro strains are
closely related to each other (<1%
nucleotide difference) but appear to be
very different from Toliara strains
(2.9% nucleotide difference), indicat-
ing the existence of two genetic line-
ages. The sequencing of the noncapsid
region (440 nucleotides corresponding
to nucleotide positions 6,705 to 7,144
of the Sabin 2 genome) confirms the
existence of two lineages derived
from different recombination events
with two nonidentified enteroviruses
of the phylogenetic cluster C. This
cluster, based on sequence similarity,
includes some coxsackieviruses and
all PV strains (3). 
We tried to identify the donor
strains for sequences in the 3’terminal
end of these recombinant strains by
aligning the nonidentified sequences
with homologous enterovirus
sequences available in a nucleotide
sequence database (FASTA, version
3.3 applied to GenBank) (4). The
highest percentages of nucleotide
sequence identity were those with
PVs and with most other cluster C
enteroviruses available in the data-
base (87% to 91% nucleotide identi-
ties). No wild PV strains have been
isolated in Madagascar since 1997
despite surveillance and investigation
of viral causes of acute flaccid paraly-
sis cases (5). Thus, that the detected
VDPVs were the product of recombi-
nation between OPV strains and two
nonpolio enteroviruses is more likely
than that they were the product of
OPV strains and two different unde-
tected wild PV strains. However, we
cannot exclude the possibility that
wild PVs were imported or circulating
silently for a while.
In response to the outbreak, the
local health authorities conducted
house-to-house vaccination with
OPV. Further field investigations
were carried out to determine the
extent to which VDPV had spread and
to search actively for other cases.
Data analysis is in progress.
As with the other epidemics in
Egypt and Hispaniola, VDPV circu-
lated in a province of Madagascar
with low OPV coverage (6,7).
Because a high OPV coverage rate
helps prevent the circulation of both
VDPVs and wild PVs, obtaining and
maintaining high rates of immuniza-
tion coverage are essential (8).
Moreover, two recombinant VDPV
lineages in Madagascar indicate that
recombination is frequent between
OPV and cluster C enteroviruses.
Similar recombinant VDPVs have
been implicated in the epidemics in
Hispaniola and in the Philippines
(6,9). Determining whether the neu-
rovirulence and transmissibility of
these VDPVs could be the result of
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the recombination with nonpolio
enteroviruses is important. These
VDPVs have major implications for
the cessation of immunization with
OPV after certification that wild PV
has been eradicated.
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West Nile Virus
Infection in
Crocodiles 
To the Editor: Recently West Nile
virus (WNV) infection has been
reported in three alligators (Alligator
sp.) from central Florida (1) and one
captive crocodile monitor (Varanus
salvadori) with neurologic signs from
the District of Columbia and
Maryland area (2). These first reports
of the virus in American reptiles high-
light the possible role of this group of
vertebrates in the WNV life cycle. To
our knowledge, WNV in a reptile was
reported only once before in a sero-
survey conducted in Israel from 1965
to 1966, in which 22 reptiles and 96
amphibians were tested for hemagglu-
tination-inhibiting antibodies against
several viruses, including WNV; one
turtle (Clemmys caspica) was
seropositive (3). Experimental infec-
tion of the lake frog (Rana ridibunda)
with a Russian strain of WNV result-
ed in high levels of viremia (4). At
present, the role of reptiles and
amphibians in the life cycle and epi-
demiology of WNV is not known.
We report, for the first time, WNV
infection in crocodiles (Crocodylus
niloticus). To assess the potential role
of crocodiles in the life cycle of WNV
in Israel, serum specimens were col-
lected from 20 healthy crocodiles on a
commercial farm in the Negev Desert,
in southern Israel (31°14′N, 34°19′E).
The crocodiles came from two sepa-
rate breeding farms (32°03′N,
35°26′E and 30°18′N, 35°07′E) in the
Syrian-African Rift Valley, which is
on the main route of bird migration
from Africa to Europe. Five males and
15 females, 1–2.5 years of age, were
examined. Blood was withdrawn from
the crocodiles’ ventral caudal vein,
separated by centrifugation, and kept
at –20°C until analyzed. Neutralizing
antibody titers were determined
against WN-goose-98 (5) and
attempts to isolate the virus were per-
formed by using Vero cell culture (6)
and by using direct reverse transcrip-
tion–polymerase chain reaction (RT-
PCR) on the serum specimens. To
eliminate the possibilities of nonspe-
cific reaction, all serum samples were
concurrently tested for the only other
flavivirus known to be present in
Israel; Israeli turkey meningo-
encephalitis virus (ITV) (7). Because
ITV does not produce cytopathic
effects (CPE) in Vero cells, virus neu-
tralization was conducted on BHK
cells for both WNV and ITV by using
WN-goose-98 and ITV (vaccine
strain). In this case, the virus stocks
(10-4.2  50% tissue culture infective
dose) were diluted 1:400, and virus
neutralization titers were checked 3
days later.
Viral RNA was extracted from
serum samples with the QIAamp
RNA blood kit (QIAGEN, Valencia,
CA) , according to the manufacturer’s
protocol and resuspended in 30 µl of
RNase-free water. The primer pair
WN240-Kun848 (respective genome
positions 5′: 848 and 1,645) was used
to synthesize an 800-bp product in the
E gene region (8,9). The resulting
DNA fragment was visualized on